IQVIA and its Data-as-a-Service (DaaS+) technology have been chosen by Boehringer Ingelheim in a new, strategic long-term collaboration.

In the partnership, Boehringer Ingelheim will use the DaaS+ platform to accelerate its global commercial data harmonization and transformation efforts. Boehringer Ingelheim will benefit from global product mastering and efficient data management.

Also, the seamless access provided to IQVIA’s data will enable data-driven decision-making.

How IQVIA’s DaaS+ Impacts Scale-Up

According to IQVIA, all of this this will help Boehringer Ingelheim scale its commercial data products and analytics ambitions. Those properties span various therapeutic areas and regional teams under Boehringer Ingelheim’s global data model.

To illustrate that, IQVIA said it anticipates producing harmonized data for market, brand, and franchise reporting across 59 countries. The partnership will additionally support upcoming launches and is designed to enhance existing market performance.

Justin Gale, Boehringer Ingelheim Global Head of Data Excellence, said the company was excited to work with IQVIA’s DaaS+. He explained that global commercial datasets will be seamlessly ingested into this unified platform. This in turn would be directly integrated into Boehringer Ingelheim’s cloud infrastructure.

“We believe this platform would drive significant efficiencies in our data operations,” Gale said. He added that this includes affording advanced analytics and innovative use cases. Altogether, he said the agreement is “paving the way for transformative insights and decision-making.”

Other Boehringer Ingelheim News

Earlier in the week, Boehringer Ingelheim disclosed another new partnership, this one with Simcere. In this collaboration, the parties agreed to develop SIM0709, a pre-clinical bispecific antibody, for treatment of inflammatory bowel disease. Boehringer Ingelheim receives global rights to the asset outside of greater China.

Boehringer Ingelheim was also, in December 2025, one of nine major pharmaceutical companies to reach agreement with the White House. This concerned President Donald Trump’s mandate for the companies to adopt most-favored-nation drug pricing.